Pruritic rash secondary to cendakimab, an investigative IL-13 inhibitor
Publication
, Journal Article
Gamada, DM; Crimmins, J; Leiman, DA; Whitley, MJ
Published in: Jaad Case Reports
February 1, 2026
Duke Scholars
Published In
Jaad Case Reports
DOI
EISSN
2352-5126
Publication Date
February 1, 2026
Volume
68
Start / End Page
87 / 89
Related Subject Headings
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Gamada, D. M., Crimmins, J., Leiman, D. A., & Whitley, M. J. (2026). Pruritic rash secondary to cendakimab, an investigative IL-13 inhibitor. Jaad Case Reports, 68, 87–89. https://doi.org/10.1016/j.jdcr.2025.11.029
Gamada, D. M., J. Crimmins, D. A. Leiman, and M. J. Whitley. “Pruritic rash secondary to cendakimab, an investigative IL-13 inhibitor.” Jaad Case Reports 68 (February 1, 2026): 87–89. https://doi.org/10.1016/j.jdcr.2025.11.029.
Gamada DM, Crimmins J, Leiman DA, Whitley MJ. Pruritic rash secondary to cendakimab, an investigative IL-13 inhibitor. Jaad Case Reports. 2026 Feb 1;68:87–9.
Gamada, D. M., et al. “Pruritic rash secondary to cendakimab, an investigative IL-13 inhibitor.” Jaad Case Reports, vol. 68, Feb. 2026, pp. 87–89. Scopus, doi:10.1016/j.jdcr.2025.11.029.
Gamada DM, Crimmins J, Leiman DA, Whitley MJ. Pruritic rash secondary to cendakimab, an investigative IL-13 inhibitor. Jaad Case Reports. 2026 Feb 1;68:87–89.
Published In
Jaad Case Reports
DOI
EISSN
2352-5126
Publication Date
February 1, 2026
Volume
68
Start / End Page
87 / 89
Related Subject Headings
- 3202 Clinical sciences